L-Tyrosine and ADHD: What the Evidence Says

Does L-tyrosine help ADHD?

Current clinical evidence does not support L-tyrosine as an ADHD treatment. The direct study located for this guide was a 1988 single-blind trial in seven children with attention deficit disorder and hyperactivity. None showed significant improvement. That is too small and old to prove ineffectiveness for every person, but it is also far too weak to justify a treatment claim.

L-tyrosine is involved in catecholamine synthesis, including dopamine and norepinephrine pathways. A plausible biochemical pathway is not the same as demonstrated symptom improvement, better functioning, or acceptable long-term safety in children or adults with ADHD.

The direct ADHD evidence is one small negative study

Eisenberg and colleagues gave oral tyrosine to seven outpatient children in a single-blind clinical study. The authors reported no significant improvement. The design lacked a large sample and the modern diagnostic, registration, and reporting standards expected today.

The correct conclusion is narrow: direct clinical evidence is insufficient, and the small study that exists did not show a meaningful benefit. It would be inaccurate to replace that conclusion with the claim that tyrosine boosts dopamine and therefore treats ADHD.

Why healthy-adult cognition studies do not answer ADHD

Different population, stressor, task, and outcome.

Selected L-tyrosine cognition studies
Study	Participants	Protocol	Result and relevance
Deijen et al., 1994Noise stress	16 healthy young adults	100 mg/kg once	Two stress-sensitive tasks improved. This was not an ADHD study.
Thomas et al., 1999Multitasking	20 healthy adults	150 mg/kg once	Working-memory accuracy improved under multitasking, not simple-task conditions.
Steenbergen et al., 2019Cognitive load	70 healthy volunteers	2 g once	Tyrosine worsened cognitive flexibility under high cognitive load.
McAllister et al., 2024Virtual stress drill	80 young adults	2 g once	Stress biomarkers did not improve; one Stroop measure favored tyrosine.

What ADHD guidelines recommend instead

The American Academy of Pediatrics guideline centers diagnosis, behavioral interventions, school support, and FDA-approved medications according to age and clinical context. NICE similarly recommends evidence-based assessment and management, along with balanced diet, good nutrition, and regular exercise. Neither guideline presents L-tyrosine as an ADHD treatment.

This does not mean nutrition is irrelevant. It means a dietary amino acid should not displace diagnosis, medication review, behavioral care, sleep assessment, or management of coexisting conditions.

What the dose and safety limits mean

Healthy-adult experiments often used large single doses calculated by body weight or fixed at 2 g. Those amounts were research exposures, not ADHD dosing recommendations. Their short follow-up does not establish daily use in a child, teenager, or adult taking stimulant or non-stimulant medication.

One severe-stress study reported higher anger ratings with tyrosine, while a cognitive-load study found worse flexibility. Mixed findings are another reason not to turn a mechanism into a predictable benefit.

A person with ADHD should discuss any supplement with the clinician managing treatment, especially when prescription medication, thyroid disease, a metabolic disorder, pregnancy, or breastfeeding is involved.

The evidence-based conclusion

L-tyrosine is not an evidence-based replacement for ADHD treatment. The direct clinical evidence is minimal and negative, while the better-known cognition studies involve healthy adults under acute stress rather than people with ADHD. The most defensible role for this ingredient today is as a research question, not a proven treatment.

See our pregnenolone evidence guide for another example of why condition-specific trials should not be expanded into broad supplement claims.